

# Labcorp, OmniSeq launch NGS genomic profiling device

July 2021—Labcorp and OmniSeq announced the launch of OmniSeq Insight, a pan-cancer, solid tumor test that combines genomic and immune profiling, including tumor mutational burden, microsatellite instability, and immune gene expression, and integrates next-generation sequencing technology.

Test results are presented in a report that summarizes all FDA-approved therapies and immunotherapies that match the patient's tumor profile and identifies clinical trials for which a patient may be eligible, within 200 miles of the patient's home. The report provides evidence-based recommendations specific to individual test results through the use of a proprietary database sourced from biologic and scientific literature, including National Comprehensive Cancer Network guidelines.

OmniSeq Insight is available to U.S.-based clinicians exclusively through Labcorp and in Canada through Dynacare, a Labcorp company. The test is also available to global biopharmaceutical companies exclusively through Labcorp Drug Development.

[Labcorp](#), 336-229-1127

[OmniSeq](#), 800-781-1259